RNA interference (RNAi) offers a fast and easy system to study gene functions. However, the traditionally used small interfering RNAs (siRNAs) can exhibit pronounced and problematic off-target effects ...

RNA interference (RNAi) is a key biological process that leads to the silencing of gene expression. RNAi can be initiated by a cell in response to pathogenic nucleic acids to bring about a targeted ...

According to SNS Insider, the global RNAi Technology Market was valued at USD 3.02 billion in 2024 and is projected to reach USD 9.03 billion by 2032, expanding at a CAGR of 14.68% over 2025–2032. RNA ...

(Nasdaq: ALNY), a leading RNAi therapeutics company, and collaborators at Radboud University Nijmegen Medical Centre in the Netherlands announced today that they have published new pre-clinical ...

DUBLIN--(BUSINESS WIRE)--The "RNA-interference (RNAi) Market - Growth, Trends, and Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering. The RNA-interference (RNAi) ...

Ribonucleic acid (RNA) interference is a relatively new technique in which small molecules called short interfering RNA (siRNA) can be inserted into cells to turn off a chosen gene. The potential uses ...

Using RNA to interfere with a gene’s expression of disease-causing proteins is a validated therapeutic approach, but so far, the products in this drug class only address liver proteins. Reducing ...

— Milestone Achievement Reflects First Investigational Candidate to Emerge Under Multi-Target Collaboration and Triggers $10 Million Payment to Dicerna — – Lilly Targeting Initiation of Phase 1 ...

- Company Expects to Initiate a Phase 1 Study in Early-Onset Alzheimer’s Disease in Early 2022, with Initial Human Data at or Around Year-End 2022 - - ALN-APP Marks the Industry’s First-Ever RNAi ...

Alnylam and Collaborators Publish New Pre-clinical Results on Ex Vivo Applications of RNAi to Enhance Dendritic Cell Vaccines for Cancer – RNAi Silencing of PD-1 Ligands Significantly Boosts Dendritic ...